4-吗啉喹唑啉类PI3K抑制剂的合成及活性研究

目的寻找具有新型骨架结构的磷脂酰肌醇3激酶(PI3K)抑制剂。方法基于活性化合物,利用"杂交"设计原理,设计和合成了系列4-吗啉喹唑啉类衍生物。结果目标化合物经1HNMR、质谱确证结构,并评价了其对Rh30细胞的增殖抑制活性。结论大部分化合物具有较好的抑制活性,化合物8b的活性最强,其IC50达0.8μmol.L-1。4-吗啉喹唑啉是一类新型的PI3K抑制剂骨架,值得进一步进行结构修饰研究。     

四氢苯并咪唑类衍生物的合成及其环氧合酶-2抑制活性

目的 寻找新型不良反应小的环氧合酶-2(COX-2)选择性抑制剂.方法 结合典型COX-2选择性抑制剂基本结构特征,设计并合成一系列新型四氢苯并咪唑类化合物.采用化学发光法测试化合物对环氧合酶-2的抑制活性.结果与结论 设计并合成了13个新型四氢苯并咪唑类化合物,其结构经元素分析、1H-NMR、13C-NMR和MS确证,所有化合物均未见文献报道.部分化合物对环氧合酶-2的抑制活性结果表明,化合物1、3、6对COX-2有一定的抑制作用.     

四氢异喹啉-噁二唑类非共价型蛋白酶体抑制剂研究初探

目的探索四氢异喹啉-噁二唑类非共价型蛋白酶体抑制剂的可行性。方法基于拼合原理,将新型非共价型蛋白酶体抑制剂PI-1833(5)的1,2,4-噁二唑靶头与本研究组发现的四氢异喹啉脲拟肽骨架相拼合,设计了四氢异喹啉-噁二唑类非共价型蛋白酶体抑制剂,合成了N-((3-苯基-1,2,4-噁二唑-5-基)甲基)-3,4-二氢异喹啉-2(1H)-甲酰异丙胺(8),并采用MTT法评价其对人胃癌细胞MGC-803的生长抑制活性;利用分子对接的方法分析化合物与20S蛋白酶体的结合状态。结果与结论化合物8在10μmol·L~(-1)浓度下没有显示出抗肿瘤活性;通过比较化合物5和8与20S蛋白酶体的对接结果,发现化合物8不产生活性的主要原因可能是噁二唑和四氢异喹啉之间的连接臂柔性不够,提示进一步研究的重点应该是对连接臂的优化。     

CI-949及其相应的吲哚酰胺基四唑类:一类新的潜在的抗变应性药物

一系列呋喃[3,2-b]吲哚类化合物对人类嗜碱性白细胞组胺释放具有抑制作用,随后,对其在化学结构上进行了修饰,制备了一系列吲哚酰胺基四唑类化合物。其中CI-949(5-甲氧基-3-(1-甲基乙氧基)-1-苯基-N-1H-四唑-5-基-1H-吲哚-2-羧酰胺精氨酸盐)为临床上有希望的抗过敏药。结构-活性关系的研究通过检测酰胺基四唑类对由抗-IgE抗体引起的人类白细胞组胺释放有无抑制作用,研究其结构与活性的关系。凡吲哚核上含有3-烷氧基、5-甲氧基以及1-苯基取代基的化合物都具有令人满意的抑制组胺释放作用(表1,略)。药物活性有赖于吲哚5位或6位(R_1)上甲氧基或卤素的取代,在吲哚1位(R_2)上由苯基取代,其活性大于用烷基取     

新型6,7-二甲氧基-4-(2-氟苯氧基)喹啉类c-Met抑制剂的设计、合成及生物活性研究

基于卡博替尼(cabozantinib)和foretinib的化学结构,通过改变中间链,设计合成了一系列含有哌嗪酰胺的6,7-二甲氧基-4-(2-氟苯氧基)喹啉类c-Met抑制剂。这些化合物未见文献报道,其结构通过MS和NMR确证。采用酶联免疫吸附测定(ELISA)法和MTT法测定了目标化合物对c-Met的抑制活性和对人结肠癌细胞(HT-29)、人肺癌细胞(H460)、人非小细胞肺癌细胞(A549)和人胃癌细胞(MKN-45)的细胞毒性。结果表明,4-(4-氯苯基)-N-[4-[(6,7-二甲氧基-4-喹啉)氧基]-3-氟苯基]哌嗪-1-甲酰胺(1b)、4-(3-氯苯基)-N-[4-[(6,7-二甲氧基-4-喹啉)氧基]-3-氟苯基]哌嗪-1-甲酰胺(1h)和4-(2-氯苯基)-N-[4-[(6,7-二甲氧基-4-喹啉)氧基]-3-氟苯基]哌嗪-1-甲酰胺(1j)对HT-29、H460、A549和MKN-45细胞的抑制活性明显优于对照药卡博替尼。其中,化合物1h和1j对c-Met具有较强的抑制活性,其IC50值分别为0.007 2和0.009 8 μmol/L。     

埃索美拉唑镁的合成

2-羟甲基-3,5-二甲基-4-硝基吡啶经氯化亚砜氯化后得2-氯甲基-3,5-二甲基-4-硝基吡啶盐酸盐(3),3与5-甲氧基-2-巯基苯并咪唑缩合得5-甲氧基-2[(3,5-二甲基-4-硝基-2-吡啶基)甲硫基]-1H苯并咪唑(4),4经不对称氧化得5-甲氧基-2-[[(3,5-二甲基-4-硝基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑(5),5再通过甲氧基化后得埃索美拉唑钠(6),最后6与氯化镁反应得埃索美拉唑镁,总收率约73.6％(以2-羟甲基-3,5-二甲基-4-硝基吡啶计).     

新型3-草酰胺-2-苯基吲哚衍生物的合成及其黄体细胞生长抑制活性的研究(英文)

本文报道以苯肼为原料合成了6个2-苯基-3-草酰胺基吲哚衍生物1a～f,其结构均未见文献报道。经初步体外试验结果表明,所被测试的6个目标化合物均具一定的离体黄体细胞生长抑制活性,且2-(4-甲氧苯基)吲哚化合物1b～d的活性明显高于2-苯基吲哚化合物1a。但在1b的吲哚氮上引入甲基或异丙基对活性没有影响。     

新型吲哚胺2,3-双加氧酶1抑制剂的合成及活性研究

目的设计合成2类1H-吲唑类新化合物,并测试其吲哚胺2,3-双加氧酶1(IDO1)抑制活性。方法以肿瘤免疫关键调控蛋白IDO1作为靶标,依据IDO1活性位点的关键药效团特征,利用合理药物设计方法,以前期研究获得的高活性化合物作为先导化合物,设计合成了2类1H-吲唑类衍生物,并测试其体外IDO1酶抑制活性。采用分子对接软件DOCK6进行分子对接模拟并分析化合物的构效关系。结果与结论合成了5个1H-吲唑类衍生物,均表现出不同程度的IDO1抑制活性,其中化合物2a和3b的抑制活性较好,在100μmol·L~(-1)时的抑制率均为69%。构效关系和分子对接研究显示,4位连接基团的结构对化合物活性影响很大,1H-吲唑类化合物还有很大结构优化空间,极具开发潜力,可为靶向IDO1的肿瘤免疫治疗提供候选化合物。     

4-(4-甲氧基苯基)-3,4-二氢-2(1H)-喹啉酮的合成及抗惊厥作用研究

目的筛选抗惊厥活性的化合物,寻找新型抗癫痫药物。方法以肉桂酸为原料,对其化学结构进行优化,合成了4-(4-甲氧基苯基)-3,4-二氢-2(1H)-喹啉酮。采用最大电休克发作实验(MES)测定其抗癫痫活性。结果采用红外光谱、核磁共振氢谱和质谱确定了化学结构。经药理活性筛选发现4-(4-甲氧基苯基)-3,4-二氢-2(1H)-喹啉酮具有抗惊厥作用。结论本合成路线简单、产物易分离,为开发新的抗癫痫药物提供了新思路。     

(2R,3S)-2-[(R)-1-[3,5-二(三氟甲基)苯基]乙氧基]-3-(4-氟苯基)吗啉盐酸盐的合成

对甲氧基苯甲醛(3)和2-氨基乙醇进行还原胺化反应得2-(4-甲氧基苄胺基)乙醇(4),4和乙醛酸经成环反应得2-羟基-4-对甲氧基苄基吗啉-3-酮(5),5和三氟乙酐反应得6后与(R)-1-[3,5-二(三氟甲基)苯基]乙醇(7)缩合,再经结晶诱导不对称转化、格氏反应、氢化脱保护及成盐反应制得阿瑞吡坦关键中间体(2R,3S)-2-[(R)-1-[3,5-二(三氟甲基)苯基]乙氧基]-3-(4-氟苯基)吗啉盐酸盐,总收率约18%(以3计)。     

祖师麻化学成分研究

目的 研究祖师麻的化学成分。方法 采用硅胶柱色谱、Pre-TLC、Pre-HPLC等方法进行分离纯化,根据理化常数和波谱数据鉴定结构。结果 从祖师麻提取物中分离得到7个已知化合物,分别鉴定为1-(4-羟基-3,5-二甲氧基苯基)-1,2-丙二酮（1）、4-羟基-3,5-二甲氧基苯甲醛（2）、4-甲基-7-羟基香豆素（3）、伞形花内酯（4）、7-羟基-8-甲氧基香豆素（5）、祖师麻甲素（6）和 α-D-吡喃果糖（7）。结论 化合物1为新天然产物,化合物2、3、7是首次从该属植物中分离得到。     

Lignans from the flower buds of Magnolia liliflora Desr

Six new lignans, 1- 6, along with six known compounds were obtained from the flower buds of Magnolia liliflora Desr. The new lignans were elucidated as (1 S*,2 R*,5 S*,6 S*)-2-(3,5-dimethoxyphenyl)-6-(3,4-methylenedioxyphenyl)-3,7-dioxabicyclo[3.3.0]octane (1), (1 R*,2 R*,5 R*,6 S*)-2-(3,5-dimethoxyphenyl)-6-(3,4-methylenedioxyphenyl)-3,7-dioxabicyclo[3.3.0]octane (2), (1 R*,?2 R*,5 R*,6 S*)-2,6-bis (3,5-dimethoxyphenyl)-3,7-dioxabicyclo[3.3.0]octane (3), (1 R*,2 S*,5 R*,6 R*)-2-(3,4-methylenedioxyphenyl)-6-(3,5-dimethoxyphenyl)-3,7-dioxabicyclo[3.3.0]octane ( 4), (7' S*,8 R*,8' R*)-3,5'-dimethoxy-3',4,9'-trihydroxy-7',9-epoxy-8,8'-lignan (5), and (7' R*,8' S*)-3,3',4,5'-tetramethoxy-7-en-7',9-epoxy-8,8'-lignan (6), by the analysis of 1D and 2D-NMR as well as HRESIMS data. The capacity of compound 1 to protect against damages to the DNA of rat lymphocyte cells induced by UV irradiation was assessed by the comet assay. It showed stronger antigenotoxicity than ascorbic acid from 6×10(-3)?mmol·L(-1) to 6×10(-6)?mmol·L(-1).     

Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases

7-Substituted 3-aryl-1,6-naphthyridine-2,7-diamines and related 2-ureas are inhibitors of fibroblast growth factor receptor-1 (FGFR-1) and vascular endothelial growth factor receptor-2 (VEGFR-2). 3-(3,5-Dimethoxyphenyl) and 3-phenyl analogues were prepared from 7-acetamido-2-tert-butylureas by alkylation with benzyl omega-iodoalkyl ethers, debenzylation, and amination, followed by selective cleavage of the 7-N-acetamide. 3-(2,6-Dichlorophenyl) analogues were prepared from the 7-fluoro-2-amine by displacement with substituted alkylamines, followed by selective acylation of the resulting substituted naphthyridine-2,7-diamines with alkyl isocyanates. The 3-(3,5-dimethoxyphenyl) derivatives were low nanomolar inhibitors of both FGFR and VEGFR and were highly selective (>100-fold) over PDGFR and c-Src. Variations in the base strength or spatial position of the 7-side chain base had only small effects on the potency (<5-fold) or selectivity (<20-fold). The 3-(2,6-dichlorophenyl)-2-urea derivatives were slightly less active against VEGFR and less selective, being more effective against PDGFR (ca. 10-fold) and c-Src (ca. 500-fold). The 3-(3,5-dimethoxyphenyl)-1,6-naphthyridines were generally more potent than the corresponding pyrido[2,3-d]pyrimidines against both VEGFR and FGFR (2- to 20-fold), with only slightly increased PDGFR and c-Src activity. The 3-(3,5-dimethoxyphenyl)-1,6-naphthyridine 2-ureas were also low nanomolar inhibitors of the growth of human umbilical vein endothelial cells (HUVECs) stimulated by serum, FGF, or VEGF, at concentrations that did not affect the growth of representative tumor cell lines, and were more (3- to 65-fold) potent than the corresponding pyrido[2,3-d]pyrimidines.     

Synthesis,biological evaluations and molecular modelling studies of novel indolin-2-ones designing as FGFR inhibitors

A series of novel 3,5-disubstituted indolin-2-ones were designed and synthesized as selective FGFR inhibitors. In the design process of 3,5-disubstituted indolin-2-ones for FGFRs, molecular docking studies were performed to generate and optimize novel compounds which have FGFR inhibitory potency, theoretically. In vitro enzyme inhibitory and selectivity profiles of the synthesized compounds, and their cytotoxicity against NIH-3T3 cells were evaluated. According to enzyme inhibition assay, compound A1 (FGFR1-4; IC₅₀ = 19.82; 5.95; 1419; 37150 nM), compound A5 (FGFR1-4; IC₅₀ = 1890; Nd; 6.50; 18590 nM) and compound A13 (FGFR1-4; IC₅₀ = 6.99; 1022; 17090; 8993 nM) have displayed best inhibitory potency against FGFR2, FGFR3 and FGFR1, respectively. The studied compounds have displayed low affinity to FGFR4 in comparison with other isoforms. Molecular docking study data were used to determine the binding orientations of the synthesized compounds inside FGFRs in accordance with enzyme inhibition assay data. Molecular dynamics simulations and free energy calculations were performed to determine stability, binding modes and dynamics behaviors of compound A1, A5 and A13 inside FGFR-2, FGFR-3 and FGFR-1, respectively. The compounds bearing aromatic groups at the C5 position of indolin-2-one could be lead compounds for the development of more effective and selective FGFR1-3 inhibitors.     

Norlignans from Pouzolzia zeylanica var. microphylla and their nitric oxide inhibitory activity

Five new compounds, pouzolignan F [4-hydroxy-3-(3,5-dihydroxyphenyl)-2-[bis(4-hydroxy-3-methoxyphenyl)methyl]butyl acetate] (1), pouzolignan G [4-hydroxy-3-(3,5-dihydroxyphenyl)-2-[(4-hydroxy-3,5-dimethoxyphenyl)(4-hydroxy-3-methoxyphenyl)methyl]butyl acetate] (2), pouzolignan H [1,4-dihydroxy-3-(3,5-dihydroxyphenyl)-2-[bis(4-hydroxy-3-methoxyphenyl)methyl]butane] (3), pouzolignan I [1,4-dihydroxy-3-(3,5-dihydroxyphenyl)-2-[(4-hydroxy-3,5-dime thoxyphenyl)-(4-hydroxy-3-methoxyphenyl)methyl]butane] (4), and pouzolignan J [1,4-dihydroxy-3-(3,5-dihydroxyphenyl) -2-[(3,4,5-trimethoxyphenyl)(4-hydroxy-3-methoxyphenyl)methyl]butane] (5), along with two known compounds, indolyl-3-carboxylic acid (6) and uracil (7), were isolated from the aerial parts of Pouzolzia zeylanica (L.) Benn. var. microphylla (Wedd.) W.T.Wang. The structures of these compounds were characterized based on spectroscopic methods, including IR, NMR (¹H–¹H COSY, HSQC, HMBC, and NOESY), and HR-ESI/TOF-MS experiments. All the new norlignans were assayed for inhibitory activity against lipopolysaccharide (LPS)-induced nitric oxide (NO) production in mouse peritoneal macrophages.     

Synthesis and monoamine oxidase inhibitory activities of 1-thiocarbamoyl-3,5-diphenyl-4,5-dihydro-1H-pyrazole derivatives

Ten new 1-thiocarbamoyl-3-(phenyl and/or 4-substituted phenyl)-5-(3,4-dimethoxyphenyl and/or 2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole derivatives were synthesized by reacting 1,3-diphenylpropen-1-ones and thiosemicarbazide. The chemical structures of the compounds were verified by means of their IR, 1H-NMR, ESI-MS spectroscopic data and elementary analyses. All the compounds were investigated for their ability to selectively inhibit monoamine oxidase (MAO) by in-vitro tests. Monoamine oxidase was isolated and purified from the mitochondrial extracts of rat-liver homogenates and human platelets. Monoamine oxidase inhibitory activities of the compounds were compared with pargyline and clorgyline. Most of the compounds inhibited the total activity of rat liver homogenates. The monoamine oxidase-A inhibitory effects of 1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole and 1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole were detected as potent as clorgyline. Selective and irreversible inhibition of rat liver monoamine oxidase-A by synthesized compounds have promising features for designing the new selective monoamine oxidase A inhibitors as potent and reliable anti-depressants in the future.     

Novel cadinane and norcadinane sesquiterpenes and a new propanoate from Goldfussia psilostachys

Three new compounds, goldfussins A (1) and B (2) and goldfussinol (3), and sixteen known compounds were isolated from the ethanolic extract of the whole plants of Goldfussia psilostachys. The structures of the new compounds were elucidated as a novel cadinane sesquiterpene, 1,8-dimethyl-5-hydroxymethyl-9-oxo-6,7,8,9-tetrahydronaphtho[2,1- b]furan (1), a novel norcadinane sesquiterpene, 4-acetyl-3-hydroxy-1-hydroxymethyl-6-methyl-5-oxo-5,6,7,8-tetrahydronaphthalene (2) and methyl 3-hydroxy-2-(3,5-dimethoxy-4-hydroxyphenyl)-propanoate (3) on the basis of spectral data.     

南岭柞木化学成分

目的对南岭柞木Xylosma controversum Clos茎的化学成分进行研究。方法应用各种色谱方法分离,应用波谱技术确定结构。结果分离鉴定了13个化合物,分别是：（-）-丁香树脂酚（1）,丁香树脂酚-4-O-β-D-葡萄糖苷（2）,丁香树脂酚-4,4＇-O-β-D-双葡萄糖苷（3）,（±）-儿茶素（4）,儿茶素-3-O-β-D-葡萄糖苷（5）,儿茶素-5-O-β-D-葡萄糖苷（6）,1,3-bis（4-hydroxy-3,5-dimethoxyphenyl）-1,3-propanediol（7）,（R）-（＋）-大风子油酸（8）,木栓酮（9）,尿嘧啶（10）,苯甲酸（11）香草酸（12）,对羟基苯甲酸（13）。结论以上化合物均为首次从柞木属植物中分离得到。     

Synthesis of 3-(3,4-dimethoxyphenyl)-1 H-1,2,4-triazole-5-thiol and 2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole derivatives exhibiting anti-inflammatory activity

New 1-acylderivatives of 5-alkylthio-3-(3,4-dimethoxyphenyl)-4H-1,2,4-triazole (5c-f, 6d-f) were synthesized by the acylation of 5-alkylthio-3-(3,4-dimethoxyphenyl)-4H-1,2,4-triazoles (3, 4) with acyl chlorides. The compounds 3, 4 were obtained by the alkylation of 3-(3,4-dimethoxyphenyl)-1H-1,2,4-triazole-5-thiol (2) sodium salt with alkyl iodides. Compound 2 and 2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole (8) were prepared by the treatment of 3,4-dimethoxybenzoylthiosemicarbazide (1) with sodium hydroxide or acetyl chloride (and then sodium hydroxide), respectively. Related 2-acylamino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazoles (7c, e, f) were synthesized by the acylation of compound 8 with acyl chlorides. 3-(3,4-Dimethoxyphenyl)-4-phenyl-4,5-dihydro-1H-1,2,4-triazole-5-thione (9) was N-acylated with acyl chlorides or S-methylated with iodomethane to give 1-acyl-3-(3,4-dimethoxyphenyl)-4-phenyl-4,5-dihydro-1H- 1,2,4-triazole-5-thiones (10a, b) or 3-(3,4-dimethoxyphenyl)-5-methylthio-4-phenyl-4H-1,2,4-triazole (11) respectively. The synthesized compounds 6d, 7a, c, 10a, b, 11 exhibit anti-inflammatory activity.     

Novel 2-thiopyrimidine derivatives as CDK2 inhibitors: molecular modeling, synthesis, and anti-tumor activity evaluation

A novel series of pyrimidine-benzenesulfonamide derivatives as potential cyclin-dependent kinase 2 inhibitors were designed depending upon the molecular docking simulation study. This study was preceded by modification and optimization of the lead compound 4-(2-amino-4-methylthiazol-5-yl)-N-(3-nitrophenyl) pyrimidin-2-amine. The target proposed compounds were synthesized using the derivative 6-(3,4-dimethoxyphenyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile (1) as a key starting compound. Some of the synthesized derivatives were selected as representative examples to evaluate their anti-proliferative activity against cultured human Hela cell line using doxorubicin as a reference drug and the results obtained were correlated with the data of molecular modeling simulation study. The structures of the novel derivatives were confirmed on the bases of micro-analytical and spectral data.